TORONTO, May 22, 2018 /CNW/ - Beleave Inc. ("Beleave" or
the "Company") (CSE: BE; OTCQX: BLEVF) is pleased to announce that it had added another location to its network of Medical
Cannabis Clinics. The new location is located at 211 Dundas Street in London, Ontario and is
expected to open shortly.
The addition of its London, Ontario location comes just weeks after the Company closed on the
acquisition of the Medi-Green Cannabis Clinic Network (see press release dated May 10
th, 2018). London, Ontario is the Company's fourth clinic joining three
Ontario locations already open in Perth, Kingston, and Hamilton.
"The Company continues to evaluate ideal locations for expansion in Ontario and across
Canada," commented Beleave CEO Andrew Wnek. "The addition of our
London location marks the first addition in a plan to aggressively build out the Company's
clinic network."
A full list of additional Medi-Green locations listed below.
Perth, Ontario - 130 Sproule Road, K7H 3C9
Kingston, Ontario - 800 Princess Street, Unit 208, K7L 5E4
Hamilton, Ontario - 310 Barton Street, L8L 2X5
For additional patient information please contact Beleave's Director of Customer Service Anne
Whelan either via email at anne@beleave.com or by
phone at 905-517-7306.
Alternatively, to stay informed please join the company mailing list at www.beleave.com.
About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access
Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.
Forward-Looking Statements
This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking
statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project",
"should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended
to identify forward-looking information. These statements are only predictions. Although the Company believes that the
expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be
placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These
risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its
cultivation license, the Company's ability to obtain a sales license and the related timing considerations, the availability of
further financing, consumer interest in its products, competition, regulation, operational and technological risks, and
anticipated and unanticipated costs and delays. There is no assurance that the Transaction will close on the terms or within the
timeframe contemplated herein or at all. Assuming the Transaction is completed, certain risks relating to the integration
and future performance of Medi-Green may also arise. Since forward-looking information addresses future events and
conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this
news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks
including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile
on www.sedar.com .
View original content with multimedia:http://www.prnewswire.com/news-releases/beleave-expands-medi-green-cannabis-clinic-network-with-additional-location-in-london-ontario-300652657.html
SOURCE Beleave Inc.
View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2018/22/c1346.html